Xia Yu
Tracked across 1 events · 7 articles · First seen Jun 12, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Akeso announced that the China — National Medical Products Administration of China has approved Gumokimab (AK111), its internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was based…
Impact: Xia Yu, Founder, Chairwoman, President and CEO of Akeso, expressed gratitude to the study participants and highlighted Akeso's growing portfolio in autoimmune diseases.
Jun 12, 2026 · 7 articles
NEWSDESK
Track Xia Yu live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard